Quantcast

Domain Registration Corp Successfully Completes Reverse Merger

May 14, 2009

SHENZHEN, China, May 14 /PRNewswire-Asia/ — Domain Registration Corp.
(OTC Bulletin Board: DOMR), today announced that on May 7, 2009, the Company
acquired all of the outstanding capital stock of China Northern Pharmacy
Holding Group Limited (“CNPH”), a British Virgin Islands corporation, and the
Board of Directors has adopted certain amendments, which include a name change
to “BioPharm Asia, Inc.”, which shall become effective upon shareholder
approval and an information statement supplied to the SEC.

CNPH is a holding company that acquired all of the outstanding stock of
China Northern Pharmacy Holding Group Limited in Hong Kong (“CNPH HK”), a
limited liability company organized under the laws of the People’s Republic of
China
(“PRC” or “China”) that owns two operating subsidiaries focused on
pharmaceutical logistics and distribution as well as the sale of various
herbal products throughout China.

The Company, through these two wholly owned operating subsidiaries, is
committed to creating a comprehensive pharmaceutical company in China through
an integrated industry chain and remains dedicated to the Chinese medicine
industry. “BioPharm Asia” intends to further expand its business scope to
cover Tibetan pharmacies, healthcare services, and medicine delivery services
comprising telephone and online order services. The Company’s revenue in 2008
was USD91 million, with a net profit of USD15.6 million.

In accordance with the successful reverse merger, “BioPharm Asia” held a
press conference and strategic cooperative agreement signing ceremony with the
local government of Tonghua County. The press conference was attended by some
institutional investors and investment banks from the United States, and
entrepreneurs from approximately 50 well-known Chinese pharmaceutical
companies, medicine distributors and pharmacy chains. Related officers from
the Chinese equivalent of the Food and Drug Administration and government
entities in Jilin province, Tonghua Municipal government and Tonghua county
government were also in attendance.

“We are very pleased to become a public company in the United States and
appreciate the broad support we have received for our efforts, as evidenced by
our recent press conference in China. The completion of this transaction
enables us to broaden our investor base, create a liquid market for our stock,
and financially support the accelerated growth of our business,” said Yunlu
Yin
, Chief Executive Officer. “We will continue to strive towards our goal of
becoming an internationally integrated healthcare and pharmaceutical group via
sustained industry mergers and acquisitions.”

China’s pharmaceutical industry has increased 16.8% annually over the past
30 years, with a total revenue of USD120.4 billion in 2008, representing an
increase of 24.9% compared to 2007. However, China’s medicine retail market
remains highly fragmented, with chain store retail as low as 20% compared to
developed countries like the U.S. that enjoy 64% of the market.

In order to combat this, on January 21, 2009, the central government
released its New Healthcare Innovation Scheme (NHIS), which will significantly
boost medicine retailing in China. As part of this new plan, online,
telephone and mail medicine retail services will be stipulated by the central
government, and these reforms will generate significant changes in the
medicine retailing market, while the most powerful distribution channels will
have significant advantages compared to the competition.

Under this climate of reform, the Company has begun implementing measures
to strengthen its core competitiveness including mergers and acquisitions, and
strategic alliances, while also enhancing its scale of operations by
introducing new products and expanding its sales networks to increase market
share.

About Domain Registration Corp (“BioPharm Asia, Inc.”)

In the process of changing its corporate name to “BioPharm Asia, Inc.”,
the Company is primarily engaged in the medicine chain business and is
complemented by a series of integrated business segments that include the
cultivation of Chinese herbal medicines, pharmaceutical production and
wholesale medicines. Following several successful acquisitions through China
Northern Pharmacy Holding Group Limited, the Company has preliminarily
completed the integration of industry chain, extending the sole trading
business (including terminal chain stores, distribution and wholesale business)
to pharmaceutical manufacturing and cultivation of medicinal raw materials.
For more information, please visit http://www.biopharmasiainc.com .

Forward-looking statement: Except for the historical information, the
matters discussed in this news release may contain forward-looking statements,
including, but not limited to, factors relating to future sales. These
forward-looking statements may involve a number of risks and uncertainties.
Actual results may differ materially based on a number of factors, including,
but not limited to, uncertainties in product demand, risks related to doing
business in China, the impact of competitive products and pricing, changing
economic conditions around the world, release and sales of new products and
other risk factors detailed in the company’s most recent annual report and
other filings with the Securities and Exchange Commission.

    For more information, please contact:

    Domain Registration Corp ("BioPharm Asia, Inc.")
     Lijun Zhang
     Tel:   +1-646-203-3666
     Email: vp@biopharmasiaco.com

    Mike Guo
     Tel:   +86-188-2025-6880, +86-755-2399-0990
     Email: cfo@biopharmasiaco.com

SOURCE Domain Registration Corp.


Source: newswire



comments powered by Disqus